Mental or Behavioral Dysfunction

FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti

2 days ago talkbio0Tagged Advisory Committees, brexpiprazole, Clinical Trials, drug efficacy, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Rexulti, sertraline, United States Food and Drug Administration

Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback

Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

4 weeks ago talkbio0Tagged alliance, Autistic Disorder, Centers for Disease Control and Prevention (U.S.), Confirmation, Gavi Vaccine, Monarez, Nominee, Robert F. Kennedy Jr., Senate, Susan, Trump administration, Vaccine Safety, Vaccines

Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

1 month ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline

1 month ago talkbio0Tagged AMPA receptor modulator, Cardiff University, Draig, DT-101, GABA Modulators, Mental Depression, neuropsychiatric drugs, SV Health Investors

Draig Therapeutics; $140M Series A; neuropsychiatric drugs; DT-101; depression treatment; AMPA receptor modulator; GABA modulators; biotech funding; Cardiff University; SV Health Investors

Sage Therapeutics Acquired by Supernus Pharmaceuticals in $561M Deal

1 month ago talkbio0Tagged Acquisition, Biogen, Deal Value, Depression, Postpartum, Drug Industry, Supernus Pharmaceuticals, Zurzuvae

Sage Therapeutics; Supernus Pharmaceuticals; acquisition; Zurzuvae; postpartum depression; biotech; pharmaceutical industry; major depressive disorder; Biogen; deal value

Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M

2 months ago talkbio0Tagged Angelini Pharma, Blackstone Life Sciences, Grin, Neurodevelopmental Disorders, pharma partnerships, radiprodil, Series D financing, Syndeio

Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

3 months ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

3 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format